Program
notice of change to virtual meeting
Please see meeting overview for important informationMONDAY, MARCH 23, 2020
- Keynote Lecture
- Session I: Rheumatic Toxicities
- Session II: Infectious Diseases
- Session III: Role of the Microbiome
- Session IV: Predictive Biomarkers
Tuesday, march 24, 2020
- Keynote Lecture
- Session V: irAEs Resulting from Combination Therapies
- Session VI: Nontraditional Nonclinical Models
- Session VII: Multidisciplinary Treatment Models
Monday, March 23, 2020
Welcome and Opening Remarks
9-9:15 A.M.
Hugh Auchincloss, National Institute of Allergy and Infectious Diseases, Rockville, Maryland
Keynote Lecture
9:15-9:45 A.M.
Understanding the immunopathogenesis of irAEs and the prospects for targeted therapy
Leonard H. Calabrese, Cleveland Clinic, Cleveland, Ohio
SESSION I: RHEUMATIC TOXICITIES
Session Moderator: Leonard H. Calabrese, Cleveland Clinic, Cleveland, Ohio
9:45-10:30 A.M.
Rheumatologic immune-related adverse events: Not our classic autoimmune diseases
Laura C. Cappelli, Johns Hopkins University School of Medicine, Baltimore, Maryland
Rheumatic toxicities associated with immune checkpoint inhibitors: The severity of myositis
Yves Allenbach, Sorbonne University, Paris, France
Seeing is believing: Imaging modalities in rheumatologic immune-related adverse events
Sarthak Gupta, National Institute of Arthritis and Musculoskeletal and Skin Diseases, Bethesda, Maryland
Panel Discussion
10:30-11:00 A.M.
Break
11:00-11:30 A.M.
Session II: Infectious Diseases
Session Moderator: Virginia Sheikh, U.S. Food and Drug Administration, Silver Spring, Maryland
11:30 A.M.-12:15 P.M.
Effects of immune checkpoint blockade on HIV latency
Rafick-Pierre Sékaly, Case Western Reserve University, Cleveland, Ohio
Preclinical TB work in Macaques
Dan Barber, National Institute of Allergy and Infectious Diseases, Bethesda, Maryland
PD-1 inhibitors for the treatment of progressive multifocal leukoencephalopathy
Irene Cortese, National Institute of Neurological Disorders and Stroke, Bethesda, Maryland
Panel Discussion
12:15-12:45 P.M.
Lunch Break
12:45-2 p.m.
Session III: Role of the Microbiome
Session Moderator: Giorgio Trinchieri, National Cancer Institute, Bethesda, Maryland
2:00-2:45 p.m.
The role of the gut-tumor axis in tumorigenesis
Florencia McAllister, MD Anderson Cancer Center, Houston, Texas
Treatment of refractory melanoma patients with fecal microbiota transplants and immunotherapy
Gal Markel, Sheba Medical Center, Tel Aviv, Israel
Manipulating the microbiome to treat inflammatory cardiomyopathy
Burkhard Ludewig, Kantonsspital St. Gallen, St. Gallen, Switzerland
Panel Discussion
2:45-3:15 P.M.
Session IV:Predictive Biomarkers
Session Moderator: Douglas B. Johnson, Vanderbilt-Ingram Cancer Center, Nashville, Tennessee
3:15-4:00 P.M.
Characterizing toxicities of immune checkpoint inhibitors
Douglas B. Johnson, Vanderbilt-Ingram Cancer Center, Nashville, Tennessee
ChDefining the features of T cell responses to tumor and self-antigens as predictors of response to checkpoint inhibitor therapy
Jane Buckner, Benaroya Research Institute, Seattle, Washington
Statistical considerations for evaluating biomarkers for irAEs
Lisa McShane, National Cancer Institute, Bethesda, Maryland
Panel Discussion
4:00-4:30 P.M.
Tuesday, March 24, 2020
Welcome and keynote Lecture
9-9:45 a.m.
Norman “Ned” Sharpless, National Cancer Institute, Bethesda, Maryland
Keynote Lecture
Immune checkpoint blockade in cancer therapy: at the interface between anti-tumor and anti-self immunity
Suzanne Topalian, Johns Hopkins University School of Medicine, Baltimore, Maryland
break
9:45-10:05
Session V: iraes resulting from combination therapies
Session Moderator: Julie Brahmer, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, Maryland
10:05-10:50 a.m.
Differentiation of dermatologic irAEs for patients on combination therapies: A consultant’s perspective
Mario E. Lacouture, Memorial Sloan Kettering Cancer Center, New York, New York
Differentiating between irAEs and other AEs in combination therapies
Lilian L. Siu, Princess Margaret Cancer Centre, Toronto, Canada
irAEs from RT + ICI
Silvia Formenti, Weill Cornell Medicine, New York, New York
Panel Discussion
10:50-11:30 A.M.
Lunch Break
11:30 a.m.-12:45 p.m.
Session VI: Nontraditional Nonclinical Models
Session Moderator: Kristina Howard, U.S. FOOD AND DRUG ADMINISTRATION, Silver Spring, Maryland
12:45-1:45 P.M.
Wild mouse microbiota in preclinical research
Barbara Rehermann, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, Maryland
Programmable bacteria for cancer
Tal Danino, Columbia University, New York, New York
A better HCC model for immunotherapy, in woodchucks?
Minhyung Kim, Roswell Park Comprehensive Cancer Center, Buffalo, New York
Canine clinical trials
Melissa Renee Chambers, University of Alabama at Birmingham, Birmingham, Alabama
Panel Discussion
1:45-2:15 P.M.
Session VII: Multidisciplinary Treatment Models
Session Moderator: nicole R. Leboeuf, Dana-Farber Cancer Institute, Boston, Massachusetts
2:15-3:20 p.m.
Severe Immunotherapy Complications (SIC) Service: A model integrating clinical care and clinical- translational research
Kerry Reynolds, Massachusetts General Hospital Cancer Center, Boston, Massachusetts and
Chloe Villani, Massachusetts General Hospital/Broad Institute, Boston, Massachusetts
A multidisciplinary immune-related toxicity team and prospective clinical trials for irAEs
Jarushka Naidoo, Johns Hopkins School of Medicine, Baltimore, Maryland
Management of immune checkpoint inhibitor-related GI toxicity
Yinghong “Mimi” Wang, MD Anderson Cancer Center, Houston, Texas
Alliance A151804: Establishment of a national biorepository to advance studies of immune-related adverse events
David Kozono, Dana-Farber Cancer Institute, Boston, Massachusetts
Panel Discussion
3:20-4:00 P.M.